• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Transfus Apher Sci . SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma

tetano

Editor, Senior Moderator
Transfus Apher Sci


. 2020 Aug 25;102922.
doi: 10.1016/j.transci.2020.102922. Online ahead of print.
SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma


Latha Dulipsingh[SUP] 1 [/SUP], Danyal Ibrahim[SUP] 2 [/SUP], Ernst J Schaefer[SUP] 3 [/SUP], Rebecca Crowell[SUP] 4 [/SUP], Margaret R Diffenderfer[SUP] 3 [/SUP], Kendra Williams[SUP] 4 [/SUP], Colleen Lima[SUP] 2 [/SUP], Jessica McKenzie[SUP] 4 [/SUP], Lisa Cook[SUP] 5 [/SUP], Jennifer Puff[SUP] 5 [/SUP], Mary Onoroski[SUP] 6 [/SUP], Dorothy B Wakefield[SUP] 4 [/SUP], Reginald J Eadie[SUP] 2 [/SUP], Steven B Kleiboeker[SUP] 7 [/SUP], Patricia Nabors[SUP] 8 [/SUP], Syed A Hussain[SUP] 2 [/SUP]



Affiliations

Abstract

SARS-CoV-2 has infected millions worldwide. The virus is novel, and currently there is no approved treatment. Convalescent plasma may offer a treatment option. We evaluated trends of IgM/IgG antibodies/plasma viral load in donors and recipients of convalescent plasma. 114/139 (82 %) donors had positive IgG antibodies. 46/114 donors tested positive a second time by NP swab. Among those retested, the median IgG declined (p < 0.01) between tests. 25/139 donors with confirmed SARS-CoV-2 were negative for IgG antibodies. This suggests that having had the infection does not necessarily convey immunity, or there is a short duration of immunity associated with a decline in antibodies. Plasma viral load obtained on 35/39 plasma recipients showed 22 (62.9 %) had non-detectable levels on average 14.5 days from positive test versus 6.2 days in those with detectable levels (p < 0.01). There was a relationship between IgG and viral load. IgG was higher in those with non-detectable viral loads. There was no relationship between viral load and blood type (p = 0.87) or death (0.80). Recipients with undetectable viral load had higher IgG levels; there was no relationship between viral load, blood type or death.

Keywords: Adults; Antigens; Blood transfusion; COVID-19; COVID-19 serotherapy; Coronavirus; Coronavirus infections; Humans; Immunoglobulin G; Immunoglobulin M; Plasma; SARS virus; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Viral; Viral load.
 
Back
Top Bottom